Longitudinal Plasma Proteomics for Psoriasis Biomarkers During Secukinumab Therapy

Hongyang Zhang's dataset contains quantified expression levels of 92 inflammation-related plasma proteins from 10 patients with moderate-to-severe psoriasis before and during secukinumab therapy, plus 10 healthy controls. The data was generated using the Olink Target 96 Inflammation panel and includes longitudinal patterns identified via Mfuzz clustering. The dataset was last updated on 2026-04-24.

Use Cases

• Identify diagnostic plasma protein signatures for psoriasis based on baseline proteomic profiles.
• Analyze longitudinal changes in inflammatory mediators following IL-17A inhibition therapy.
• Validate candidate biomarkers like IL-17C for correlation with disease severity and treatment response.
• Perform functional enrichment analysis on differentially expressed proteins involved in cytokine-cytokine receptor interactions.

Strengths

• Includes longitudinal data from 10 patients collected before and during therapy.
• Quantifies 92 specific inflammation-related proteins using the standardized Olink platform.
• Contains matched data from 10 healthy controls for baseline comparison.

Limitations

• Small sample size of 10 patients, as noted by the author.
• Row count and column-level documentation are unknown, requiring inspection after download.
• The 36.7 KB file size indicates a very limited scope of data.

Provenance

Source

Hongyang Zhang via figshare.

Collection Method

Plasma proteomic quantification using the Olink Target 96 Inflammation panel, with ELISA validation.

Freshness

Last updated 2026-04-24 05:40:21; freshness should be verified.